CAJ | 학술논문

目的探讨锌指增强子结合蛋白-2（ ZEB-2）在非小细胞肺癌中的表达，并分析其表达与E-cadherin、N-cadherin、临床病理特征和预后的相关性。方法应用免疫组化方法检测ZEB-2、E-cadherin和N-cadherin在143例非小细胞肺癌中的表达，并分析ZEB-2表达与E-cadherin、N-cadherin、肿瘤临床病理特征及预后的相关性。结果 ZEB-2在非小细胞肺癌中表达阳性率为51.0％（73/143）；ZEB-2表达与E-cadherin表达呈负相关（ r＝-0.235，P＝0.005），与N-cadherin表达呈正相关（ r＝0.222，P＝0.008）；此外，ZEB-2在肺鳞癌中比在肺腺癌中有更高的表达（70.5％vs．42.4％，P＝0.002）；在TNM Ⅲ～Ⅳ期中比在Ⅰ～Ⅱ期中有更高的表达（61.3％vs．46.9％，P＝0.032）；而且ZEB-2阳性表达是患者不良预后的独立影响因素（单因素P＝0.003，多因素P＝0.048）。结论 ZEB-2在非小细胞肺癌中表达上调，引起E-cadherin表达下调和N-cadher-in表达上调，导致肿瘤侵袭能力增强，最终导致预后不良。
목적탐토자지증강자결합단백-2（ ZEB-2）재비소세포폐암중적표체，병분석기표체여E-cadherin、N-cadherin、림상병리특정화예후적상관성。방법응용면역조화방법검측ZEB-2、E-cadherin화N-cadherin재143례비소세포폐암중적표체，병분석ZEB-2표체여E-cadherin、N-cadherin、종류림상병리특정급예후적상관성。결과 ZEB-2재비소세포폐암중표체양성솔위51.0％（73/143）；ZEB-2표체여E-cadherin표체정부상관（ r＝-0.235，P＝0.005），여N-cadherin표체정정상관（ r＝0.222，P＝0.008）；차외，ZEB-2재폐린암중비재폐선암중유경고적표체（70.5％vs．42.4％，P＝0.002）；재TNM Ⅲ～Ⅳ기중비재Ⅰ～Ⅱ기중유경고적표체（61.3％vs．46.9％，P＝0.032）；이차ZEB-2양성표체시환자불량예후적독립영향인소（단인소P＝0.003，다인소P＝0.048）。결론 ZEB-2재비소세포폐암중표체상조，인기E-cadherin표체하조화N-cadher-in표체상조，도치종류침습능력증강，최종도치예후불량。
Objective To investigate the expression of zinc finger E-box binding homeobox-2(ZEB-2),E-cadherin and N-cadherin protein ,assess their correlations with clinicopathological parameters ,especially prognosis ,in non-small cell lung cancer ( NSCLC).Methods The expression level of ZEB-2, E-cadherin and N-cadherin in NSCLC was measured by immunohistochemistry .Results The positive ratio of ZEB-2 was 51.0%( 73/143 ) in NSCLC.ZEB-2 expression was negatively correlated with E-cadherin expression ( r =-0.235 , P =0.005 ) and positively correlated with N-cadherin expression(r=0.222,P=0.008).In addition,the positive ratio of ZEB-2 was higher in squamous carcinoma than in adenocarcinoma (70.5% vs.42.4%,P=0.002),and higher in TNM Ⅲ-Ⅳstage than TNMⅠ-Ⅱstage(61.3%vs.46.9%,P=0.032).Furthermore,patients with increased ZEB-2 expression had poor survival ( P=0.003 in univariate and P=0.048 in multivariate analysis ) .Conclusions The expression of ZEB-2 was increased in NSCLCs and may negatively regulate E-cadherin and positively regulate N-cadherin. Increased expression of ZEB-2 was correlated with progression and poor prognosis in NSCLC patients .